# FWO DMP Template - Flemish Standard Data Management Plan

# Version KU Leuven

Project supervisors (from application round 2018 onwards) and fellows (from application round 2020 onwards) will, upon being awarded their project or fellowship, be invited to develop their answers to the data management related questions into a DMP. The FWO expects a **completed DMP no later than 6 months after the official start date** of the project or fellowship. The DMP should not be submitted to FWO but to the research co-ordination office of the host institute; FWO may request the DMP in a random check.

At the end of the project, the **final version of the DMP** has to be added to the final report of the project; this should be submitted to FWO by the supervisor-spokesperson through FWO’s e-portal. This DMP may of course have been updated since its first version. The DMP is an element in the final evaluation of the project by the relevant expert panel. Both the DMP submitted within the first 6 months after the start date and the final DMP may use this template.

The DMP template used by the Research Foundation Flanders (FWO) corresponds with the Flemish Standard Data Management Plan. This Flemish Standard DMP was developed by the Flemish Research Data Network (FRDN) Task Force DMP which comprises representatives of all Flemish funders and research institutions. This is a standardized DMP template based on the previous FWO template that contains the core requirements for data management planning. To increase understanding and facilitate completion of the DMP, a standardized **glossary** of definitions and abbreviations is available via the following [link](https://www.fwo.be/media/1024841/glossary-flemish-standard-data-management-plan.pdf).

|  |  |
| --- | --- |
| 1. **General Project Information** | |
| Name Grant Holder & ORCID | **Prof. Dr. Thomas Tousseyn https://orcid.org/0000-0002-0397-1086** |
| Contributor name(s) (+ ORCID) & roles | Drs. Johanna Vets https://orcid.org/0000-0001-8255-4784 |
| Project number [[1]](#footnote-1) & title | 1801825N Tumor Microenvironment in Lymphoproliferative Disorders associated with viral infections and immunodeficiencies : the search for new therapeutic targets |
| Funder(s) GrantID [[2]](#footnote-2) |  |
| Affiliation(s) | x KU Leuven  ☐ Universiteit Antwerpen  ☐ Universiteit Gent  ☐ Universiteit Hasselt  ☐ Vrije Universiteit Brussel  ☐ Other:  ROR identifier KU Leuven: 05f950310 |
| Please provide a short project description | Recently, in addition to the well-established treatment regimens (surgery, radiotherapy and chemotherapy), immunotherapy has entered the scene as a major therapeutic tool in the treatment of cancer. It not only tackles the neoplastic cells (e.g. anti-CD20 in B-cell lymphoma), but also interferes with the interaction between tumor cells its non-neoplastic surrounding cells of the tumor microenvironment (TME). The characteristics of this interaction guides clinicians in their choice for personalized immunotherapy (e.g. PDL1-PD1 blockade), but, firstly, there is a need for further understanding this interaction in different cancer types, and this information is lacking in lymphoma. Secondly, there is a need for practical tools for the hematopathologist to characterize this complex interaction on the patient tumor samples. In the next decades histopathologic analysis of tumor biopsies will still be the cornerstone for diagnosis, but in daily practice pathologists rely on a sequential application of sets immunohistochemical (IHC) stainings. This is a time-consuming procedure, only partially remunerated by the RIZIV/INAMI, and only providing information on which cells are present, which proteins are expressed but not to which interactions actually matter.  With this challenging project we step up from Classic Histopathological techniques (morphology and immunohistochemistry, still being the standard in most labs) towards Next-Generation Pathology, including multi-omics technologies, like single cell-RNA seq, spatial transcriptomics (GeoMx from Nanostring) and multiplex immunofluorescence (MILAN).  We want to further elaborate on our earlier findings of the influence of EBV on the TME in EBV+ lymphomas, as we believe a detailed understanding of this TME interactions is an essential step towards precision immunotherapy.  The main objectives of this study is to unravel a discernible pattern of immune responses in patients with EBV-driven lymphomas, using novel in-depth analysis of the TME.  Understanding the interactions between tumor cells and its surrounding non-neoplastic cells will allow us to pinpoint distinctive prognostic markers tailored for individuals with IDD-LPDs and define new targets for immunotherapy. |

|  |  |
| --- | --- |
| 1. **Research Data Summary** | |
| List and describe all datasets or research materials that you plan to generate/collect or reuse during your research project. For each dataset or data type (observational, experimental etc.), provide a short name & description (sufficient for yourself to know what data it is about), indicate whether the data are newly generated/collected or reused, digital or physical, also indicate the type of the data (the kind of content), its technical format (file extension), and an estimate of the upper limit of the volume of the data [[3]](#footnote-3).   |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | |  | | | | *Only for digital data* | *Only for digital data* | *Only for digital data* | *Only for physical data* | | Dataset Name | Description | New or Reused | Digital or Physical | Digital Data Type | Digital Data Format | Digital Data Volume (MB, GB, TB) | Physical Volume | | Spatially resolved (m)IHC images | Scans made of immunofluorescence-stained human biopsy slides | Generate new data  Reuse existing data | Digital  Physical | Audiovisual  Images  Sound  Numerical  Textual  Model  Software  Other: | czi and ome tiff format | < 1 GB  < 100 GB  < 1 TB  < 5 TB  > 5 TB  NA | NA | |  |  |  |  |  |  |  |  | |  |  |  |  |  |  |  |  | |  |  |  |  |  |  |  |  | |  |  |  |  |  |  |  |  | | |
| *Guidance:*  *The data description forms the basis of your entire DMP, so make sure it is detailed and complete. It includes digital and physical data and encompasses the whole spectrum ranging from raw data to processed and analysed data including analysis scripts and code. Physical data are all materials that need proper management because they are valuable, difficult to replace and/or ethical issues are associated.* *Materials that are not considered data in an RDM context include your own manuscripts, theses and presentations; documentation is an integral part of your datasets and should described under documentation/metadata.*  [*RDM Guidance on data*](https://www.kuleuven.be/rdm/en/guidance/data-standards) | |
| If you reuse existing data, please specify the source, preferably by using a persistent identifier (e.g. DOI, Handle, URL etc.) per dataset or data type. | Not applicable |
| Are there any ethical issues concerning the creation and/or use of the data  (e.g. experiments on humans or animals, dual use)? If so, refer to specific datasets or data types when appropriate and provide the relevant ethical approval number. | Yes, human subject data; provide SMEC or EC approval number: ?  Yes, animal data; provide ECD reference number:  Yes, dual use; provide approval number:  No  Additional information: |
| Will you process personaldata*[[4]](#footnote-4)*? If so, please refer to specific datasets or data types when appropriate and provide the KU Leuven or UZ Leuven privacy register number (G or S number). | Yes (provide PRET G-number or EC S-number below)  No  Additional information:  S-55498 |
| Does your work have potential for commercial valorization (e.g. tech transfer, for example spin-offs, commercial exploitation, …)?  If so, please comment per dataset or data type where appropriate. | Yes  No  If yes, please comment: |
| Do existing 3rd party agreements restrict exploitation or dissemination of the data you (re)use (e.g. Material/Data transfer agreements, research collaboration agreements)?  If so, please explain to what data they relate and what restrictions are in place. | Yes  No  If yes, please explain: |
| Are there any other legal issues, such as intellectual property rights and ownership, to be managed related to the data you (re)use?  If so, please explain to what data they relate and which restrictions will be asserted. | Yes  No  If yes, please explain: |

|  |  |
| --- | --- |
| 1. **Documentation and Metadata** | |
| Clearly describe what approach will be followed to capture the accompanying information necessary to keep **data understandable and usable**, for yourself and others, now and in the future (e.g. in terms of documentation levels and types required, procedures used, Electronic Lab Notebooks, README.txt files, Codebook.tsv etc. where this information is recorded).  [*RDM guidance on documentation and metadata*](https://www.kuleuven.be/rdm/en/guidance/documentation-metadata)*.* | All data will be accompanied with a README file or tab that outlines the exact data collection procedure, especially important for experimental data.  All experimental work is prepared by extensive preparations, each step is logged on Labcollector in the electronic lab note book. Standard operating procedures are written out in the lab and safely stored together with the experimental data in the same folders, to allow easy recovery of the metadata. All team members have access to these metadata. |
| Will a metadata standard be used to make it easier to **find and reuse the data**?  If so, please specify which metadata standard will be used. If not, please specify which metadata will be created to make the data easier to find and reuse.  *Repositories could ask to deliver metadata in a certain format, with specified ontologies and vocabularies, i.e. standard lists with unique identifiers.* | Yes  No  If yes, please specify (where appropriate per dataset or data type) which metadata standard will be used:  All metadata for the experimental work are maintained in the lab's repository. These follow a standard format and vocabulary.  If no, please specify (where appropriate per dataset or data type) which metadata will be created: |

|  |  |
| --- | --- |
| 1. **Data Storage & Back-up during the Research Project** | |
| Where will the data be stored?  *Consult the*[*interactive KU Leuven storage guide*](https://icts.kuleuven.be/storagewijzer/en)*to find the most suitable storage solution for your data.* | Shared network drive (J-drive)  Personal network drive (I-drive)  Teams  Sharepoint online  Sharepoint on-premis  Large Volume Storage  ManGO  Digital vault  Other: Hard drive (25TB) |
| How will the data be backed up?  *What storage and backup procedures will be in place to prevent data loss?* | Standard back-up provided by KU Leuven ICTS for my storage solution  Personal back-ups I make (specify)  Other (specify)  Our lab uses a network-attached storage (NAS) system with 500 TB of storage on which a copy of the data on the hard drive is stored. This NAS system is attached to KU Leuven's network. All data stored in the NAS is backed up automatically with version control and logging. Additionally, the NAS is mirrored to prevent catastrophic disaster. |
| Is there currently sufficient storage & backup capacity during the project? If yes, specify concisely. If no or insufficient storage or backup capacities are available, then explain how this will be taken care of. | Yes  No  If no, please specify: |
| How will you ensure that the data are securely stored and not accessed or modified by unauthorized persons?  *clearly describe the measures (in terms of physical security, network security, and security of computer systems and files) that will be taken to ensure that stored and transferred data are safe.*  [*Guidance on security for research data*](https://icts.kuleuven.be/storagewijzer/en) | The data are stored on the KU Leuven servers, only accessible with double authentication.  The hard drive is stored in a locker in the lab which is only accessible with badge entrance. |
| What are the expected costs for data storage and backup during the research project? How will these costs be covered? |  |

|  |  |
| --- | --- |
| **5. Data Preservation after the end of the Research Project** | |
| Which data will be retained for at least five years (or longer, in agreement with other retention policies that are applicable) after the end of the project? In case some data cannot be preserved, clearly state the reasons for this  (e.g. legal or contractual restrictions, storage/budget issues, institutional policies...).  [*Guidance on data preservation*](https://icts.kuleuven.be/storagewijzer/en) | ​​ All data will be preserved for 10 years according to KU Leuven RDM policy  All data will be preserved for 25 years according to CTC recommendations for clinical trials with medicinal products for human use and for clinical experiments on humans  Certain data cannot be kept for 10 years (explain) |
| Where will these data be archived (stored and curated for the long-term)?  [*Dedicated data repositories*](https://www.kuleuven.be/rdm/en/policy)*are often the best place to preserve your data. Data not suitable for preservation in a repository can be stored using a KU Leuven storage solution, consult the*[*interactive KU Leuven storage guide*](https://www.kuleuven.be/rdm/en/guidance/data-sharing)*.* | KU Leuven RDR  Large Volume Storage (longterm for large volumes)  Shared network drive (J-drive) --> NAS  Other (specifiy): Hard drive stored by responsible person of the project |
| What are the expected costs for data preservation during the expected retention period? How will these costs be covered? | All costs have been covered by the departmental group. |

|  |  |
| --- | --- |
| **6. Data Sharing and Reuse** | |
| Will the data (or part of the data) be made available for reuse after/during the project?  Please explain per dataset or data type which data will be made available.  *Note that ‘available’ does not necessarily mean that the data set becomes openly available, conditions for access and use may apply. Availability in this question thus entails both open & restricted access. For more information:* [*https://wiki.surfnet.nl/display/standards/info-eu-repo/#infoeurepo-AccessRights*](https://wiki.surfnet.nl/display/standards/info-eu-repo/#infoeurepo-AccessRights) | Yes, as open data  Yes, as embargoed data (temporary restriction)  Yes, as restricted data (upon approval, or institutional access only)  No (closed access)  Other, please specify:  All imaging data will be made available to selected users via our DISSCOvery software. This software provides a safe (password-protected) repository which directly feeds from the NAS. |
| If access is restricted, please specify who will be able to access the data and under what conditions. | Data will be accessible by the team upon request of the responsible person of this project |
| Are there any factors that restrict or prevent the sharing of (some of) the data (e.g. as defined in an agreement with a 3rd party, legal restrictions)? Please explain per dataset or data type where appropriate. | Yes, privacy aspects  Yes, intellectual property rights  Yes, ethical aspects  Yes, aspects of dual use  Yes, other  No  If yes, please specify: |
| Where will the data be made available?  If already known, please provide a repository per dataset or data type. | KU Leuven RDR  Other data repository (specify): via in house developed software DISSCOvery  Other (specify) |
| When will the data be made available? | Upon publication of research results  Specific date (specify)  Other (specify) |
| Which data usage licenses are you going to provide? If none, please explain why.  *A data usage license indicates whether the data can be reused or not and under what conditions. If no licence is granted, the data are in a grey zone and cannot be legally reused. Do note that you may only release data under a licence chosen by yourself if it does not already fall under another licence that might prohibit that.*  *Check the*[*RDR guidance on licences*](https://www.kuleuven.be/rdm/en/rdr/licenses)*for data and software sources code or consult the*[*License selector tool*](https://ufal.github.io/public-license-selector/)*to help you choose.* | CC-BY 4.0 (data)  Data Transfer Agreement (restricted data)  MIT licence (code)  GNU GPL-3.0 (code)  Other (specify)  The data will be made publicly available in peer-reviewed manuscripts. |
| Do you intend to add a PID/DOI/accession number to your dataset(s)? If already available, please provide it here.  *Indicate whether you intend to add a persistent and unique identifier in order to identify and retrieve the data.* | Yes, a PID will be added upon deposit in a data repository  My dataset already has a PID  No |
| What are the expected costs for data sharing? How will these costs be covered? | The data will be shared in peer-reviewed manuscripts; approximate cost for publication is 2500-5000EUR.  These costs will covered bythe available working grants. |

|  |  |
| --- | --- |
| **7. Responsibilities** | |
| Who will manage data documentation and metadata during the research project? | PhD student Johanna Vets and the bio-informaticions of the MILAN group at the department of Imaging and Pathology |
| Who will manage data storage and backup during the research project? | PhD student Johanna Vets and the bio- informaticions of the MILAN group at the department of Imaging and Pathology |
| Who will manage data preservation and sharing? | Prof. Dr. Thomas Tousseyn + Drs. Johanna Vets |
| Who will update and implement this DMP? | Prof. Dr. Thomas Tousseyn + Drs. Johanna Vets |

1. “Project number” refers to the institutional project number. This question is optional. Applicants can only provide one project number. [↑](#footnote-ref-1)
2. Funder(s) GrantID refers to the number of the DMP at the funder(s), here one can specify multiple GrantIDs if multiple funding sources were used. [↑](#footnote-ref-2)
3. Add rows for each dataset you want to describe. [↑](#footnote-ref-3)
4. See Glossary Flemish Standard Data Management Plan [↑](#footnote-ref-4)